Librexia AF: AFIB Study


What is atrial fibrillation?

AF is a common type of arrhythmia, or irregular heartbeat. Some people with AF might feel a flutter in their chest or shortness of breath, while others have no symptoms. With AF, the heart does not pump well, which can lead to blood clots. These clots may then cause a stroke or heart attack. Some standard AF treatments are designed to prevent clots from forming but they also may increase the risk of bleeding. New options that prevent clots without increasing the risk of bleeding are needed.


About the Librexia AF Study
The main goal of the Librexia AF Study is to see if the study medication, created to prevent blood clots, is safe and effective. Researchers also want to compare the study medication with a medication that is already approved to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation (AF). This approved medication is called the comparator. Participants will have an equal chance of receiving the study medication or comparator.


Primary Study Coordinator: Catie
Phone: (662) 893-8490 Extension *3231


This is default text for notification bar